Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.
Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.
Also known as keratoconjunctivitis sicca (KCS) or dysfunctional tear syndrome
Disease of the tears & ocular surface that is secondary to several factors
Associated w/ increased osmolarity of the tear film & inflammation of the ocular surface
Dysfunction in either of the lacrimal glands, ocular surface, eyelids, meibomian glands, or associated sensory or motor nerves may lead to dry eye syndrome (DES) causing changes in the volume, composition, distribution, &/or clearance of the tear film
Tear hyperosmolarity may be due to reduced aqueous flow or excessive evaporation of tears
Tear film instability may be secondary to hyperosmolarity which results in increased evaporation of tears
Signs and Symptoms
Common ocular signs & symptoms experienced by patients that usually worsen later in the day include the following:
Blurry vision (may clear temporarily w/ blink)
Contact lens intolerance
Foreign body sensation
Increased blinking frequency
Symptoms may be aggravated by wind, air travel, low humidity, prolonged use of the eyes associated w/ decreased blink rate, or smoky environments
Increases evaporation or causes irritation that worsens dry eye syndrome (DES) symptoms
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.